Hello everyone, I'm your financial journalist and economist. Today, we're not talking about the ups and downs of the stock market, but about a "technological revolution" that could significantly improve the quality of human life—cancer vaccines.
Recently, there have been two major announcements in the medical community that have suddenly reignited the long-dormant cancer vaccine field. In simple terms, a personalized mRNA cancer vaccine developed by Moderna and Merck has made a "historical" breakthrough in the treatment of melanoma.
Many readers might be wondering: Cancer vaccines? We were vaccinated as children to prevent hepatitis B and HPV. How can we now get vaccinated against cancer? How close is this technology to becoming the next big opportunity in the pharmaceutical industry?
Don't worry; let's put aside the complex medical jargon and explain this in plain language.
---
Summary of the Key Points:
The main news is that the personalized mRNA cancer vaccine (Intismeran autogene), when combined with the immunotherapy drug pembrolizumab, has achieved a milestone success in the treatment of melanoma:
1. Impressive Data: In the 5-year follow-up of the Phase IIb study, the combined treatment reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59%.
2. Phase III Validation: In August 2026, Moderna and Merck announced that this approach met the primary endpoint (progression-free survival) and a key secondary endpoint (distant metastasis-free survival) in a larger Phase III study (INTerpath-001).
3. Significant Meaning: This is the first time that a personalized neoantigen therapy (which means a vaccine customized based on your specific tumor mutations) has shown positive results in a Phase III trial. This indicates that this technological approach is no longer just theoretical but has been proven effective by clinical data.
Next, we will break down this in five aspects to understand the logic, principles, challenges, and future prospects.
---
1. Clarifying the Concept: Cancer Vaccines Are for Treating, Not Preventing Cancer
When people hear "vaccine," they often think of prevention—like getting vaccinated against hepatitis B or HPV to avoid those diseases. However, the therapeutic cancer vaccines discussed in this news work differently.
- It's Not a Shield, but an "Arrest Warrant":
Preventive vaccines equip the immune system with defenses against viruses. Therapeutic cancer vaccines, on the other hand, provide the immune system with information about the cancer cells, telling it, "This is the enemy, catch it!"
- It's Not a Single Product, but a Strategy: Current therapeutic cancer vaccines are not a single drug; they represent a range of technical approaches, including peptides, nucleic acids (like mRNA), microbial vectors, or even cell-based vaccines.
- Universal: These vaccines target common tumor characteristics in most patients.
- Personalized: This is the focus of this news. By sequencing the patient's genes, a vaccine is created specifically for their tumor mutations, similar to having a custom suit made for each person.
- Current Status: Still in the “Trial Phase”:
Aside from a few approved vaccines (such as Sipuleucel-T for prostate cancer), most therapeutic cancer vaccines are still in clinical research. The breakthrough in melanoma is a crucial step for this field moving from the lab to clinical practice.
---
2. How Does the Immune System Get “Awakened”?
The key to how vaccines can treat cancer lies in the “cancer-immune cycle.” Imagine it as a police operation:
- Step 1: Finding the Clue (Antigen Presentation): The vaccine enters the body and is taken up by dendritic cells, which then present the unique “fingerprints” of the cancer cells to T cells.
- Step 2: The Police Respond (T Cell Activation and Migration): The T cells are activated and migrate to the tumor site.
- Step 3: Precise Attack (Killing and Release): The T cells recognize and kill the cancer cells. After the cancer cells are killed, they release more “fingerprints,” which are captured by the dendritic cells, triggering more T cells to be activated.
- Forming a Positive Feedback Loop: The more cancer cells are killed, the more clues are generated, and the more T cells are activated, creating a cycle that enhances the immune response.
3. Why Do Some Patients Respond While Others Do Not?
The reason why not all patients benefit from vaccines lies in the “immune microenvironment” around the tumor:
- Tumor’s Defense Mechanisms: Tumors have a complex ecosystem surrounding them. Some tumors have few T cells, making it difficult for vaccines to reach them. Others have immune inhibitors that weaken the T cells.
- Patient Factors: Age and immune aging can slow down the immune response. Previous treatments can also reduce the number of immune cells, reducing the vaccine’s effectiveness.
- Customization Is Essential: Because each person’s tumor microenvironment and immune state are unique, a one-size-fits-all vaccine is ineffective. Personalized mRNA vaccines can target specific mutations and, in the future, be combined with other drugs to break down the tumor’s defenses.
4. The Technical Challenge: Finding the Right Targets
The accuracy of cancer vaccines depends on the selection of antigens. Wrong targets can harm healthy cells, while the right ones can be highly effective:
- Types of Antigens: There are three types of antigens:
- Self-antigens are present in both normal and cancer cells, increasing the risk of side effects.
- Non-self-antigens (e.g., from viruses like HPV) are easier to recognize but have a limited range of application.
- Neoantigens (from tumor mutations) are highly specific and target only cancer cells, reducing side effects.
- The Screening Process: Identifying the right antigens is complex and time-consuming, involving gene sequencing, algorithmic prediction, and laboratory testing.
5. Industry Prospects: Which Cancers Are Most Promising?
Based on 281 clinical trials covering 20 types of tumors:
- Approved Vaccines: Sipuleucel-T for prostate cancer has extended survival by about 4 months.
- Leading Breakthrough: Melanoma, with impressive data from this news.
- Hot Areas: Breast cancer, brain tumors, pancreatic cancer, and lung cancer.
- Pancreatic Cancer: Known as one of the most difficult to treat, 29 trials are underway, with one showing promise in individualized mRNA vaccines.
6. Future Directions:
The future of cancer vaccines lies in collaboration and precision:
- More Precise Antigen Selection: Faster and more accurate methods for identifying effective antigens.
- More Efficient Delivery: Better ways to deliver vaccines to lymph nodes and tumors.
- Combined Treatments: Vaccines combined with immune checkpoint inhibitors and anti-angiogenic drugs.
- Dynamic Treatment: Tailored treatments based on the patient’s immune state.
---
Conclusion
Moderna and Merck’s breakthrough marks a significant step forward for personalized cancer vaccines, moving them from concept validation to clinical effectiveness. It shows that cancer is no longer an incurable disease, and we can control tumors more effectively by activating the immune system. Precision medicine is the way forward, with treatments tailored to each patient’s unique tumor. Combined treatments will be crucial for overcoming the defenses of tumors.
For investors and health enthusiasts, this is an area worth watching closely. Although the road ahead is long, the direction is clear: using the immune system as our body’s strongest weapon against cancer.